Eli Lilly and Company

Pia Pauliina Yachi

Ying Tang

Jirong Lu

Derrick Ryan Witcher

Barrett Allan

Donmienne Doen Mun Leung

Donmienne Doen Leung

Ling Liu

Peng Luan

Andrew L Glasebrook

Qing Chai

Stephanie Marie Truhlar

Yiqing Feng

Sheng-Hung Rainbow Tschang

Hector Aldaz

Andrew Charles Vendel

Petra Verdino

Kristin Paige Newburn

Andrew Lawrence Glasebrook

The present invention relates to anti-human PD-1 agonist antibodies, and uses thereof for treating autoimmune disorders such as rheumatoid arthritis or for decreasing rejection of transplanted cells and/or tissues.

PD-1 agonist antibodies and uses thereof

Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF&#x3b1;) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).

Anti-TNF-anti-IL-17 bispecific antibodies

Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (EGFR) and MET, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by EGFR and MET.

Multifunctional antibodies binding to EGFR and MET

Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA.

Anti-hepcidin-25 selective antibodies and uses thereof

Growing community of inventors

San Diego, CA, United States of America

Pia Pauliina Yachi